Study details
Enrolling now
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
Baylor College of Medicine
NCT IDNCT02291848ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
36
Study length
about 13 years
Ages
18+
Locations
3 sites in TX
About this study
This trial is testing a new treatment called tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes (CTLs) in people with multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), or smoldering myeloma. The goal is to find the safest dose and understand any side effects that might occur.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive TAA-specific CTLs
- 2.Receive TAA-specific CTLs- fixed dose
PhasePhase 1
Primary goalNumber of Patients with Adverse events
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Number of Patients with Adverse events
Body systems
Oncology